We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Patrik Jonsson is an executive vice president at Eli Lilly ... has run Lilly Diabetes and Obesity, which means he oversees everything from insulin shots to the newer, high-demand drugs now known ...

It’s a problem that has plagued European governments for decades, from the credit-crunch bank bailouts of 2008 to more recent ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments ... Lilly has a broad portfolio of medications treating many different pockets of the healthcare landscape.

American pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven effective in managing both obesity and type-2 diabetes. Vineet Gupta ...

Some people make it a New Year's resolution to improve their finances by investing in stocks. It's a laudable goal, and to ...

Patrik Jonsson is an executive vice president at Eli Lilly and president ... For the past year, Jonsson has run Lilly Diabetes and Obesity, which means he oversees everything from insulin shots to the ...